跳至主要内容
临床试验/ACTRN12614000495628
ACTRN12614000495628招募中1 期

In an obese, non-diabetic population, does twice daily dosing of a commercially available fucoidan extract over three months, when compared to placebo, lead to changes in glucose control and other markers of cardiometabolic health?

niversity of Tasmania.0 个研究点目标入组 80 人开始时间: 2014年5月12日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • Body mass index >= 30 mg/m^2

排除标准

  • - Diabetes or family history of diabetes (parents or siblings)
  • - Current smokers (participants that have smoked previously may be included, though not if they have had any cigarettes in the past 30 days or if they smoke during the study period of 3 months).
  • - Random blood glucose level above 7.8mM (during screening appointment).
  • - Fasting blood glucose level above 7mM at either study appointment.
  • - Taking more than 5 regular medicines.
  • - Taking any anticoagulant medication.
  • - Having any contraindication to anticoagulant medication (e.g. increased risk of bleeding due to a medical condition).

研究者

发起方
niversity of Tasmania.

相似试验